Goldman Sachs Maintains Buy on Amgen, Raises Price Target to $350
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Buy rating on Amgen (NASDAQ:AMGN) and raises the price target from $313 to $350.
February 08, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Amgen and increases the price target to $350.
The increase in price target by a reputable analyst firm like Goldman Sachs typically signals a strong confidence in the company's future performance. This endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100